BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...
BioCentury | Oct 31, 2020
Translation in Brief

A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx

Isolating tumor antigen-specific T cellsScripps Research Institute scientists have described in Cell a method, coined FucoID, to detect and separate T cells that react to tumor-specific antigens from bystander T cells. In FucoID, which is based on...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

AstraZeneca’s oncology R&D chief José Baselga sees the pharma’s push into ADCs as prologue for its quiet move into cell therapies, as the company builds up a stable of new modalities and targets...
BioCentury | Oct 28, 2020
Distillery Therapeutics

STK25 and TAO1 identified as schistosomiasis targets

DISEASE CATEGORY: Infectious disease INDICATION: Infectious Inhibiting the serine/threonine kinases STK25 and TAO1 in parasitic flatworms could treat schistosomiasis. An RNAi screen of 2,320 protein-encoding genes in adult Schistosoma mansoni identified 19 genes encoding protein kinases involved in...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
BioCentury | Oct 3, 2020
Product Development

Data Bytes: Poxel’s place in the NASH pack

Though Poxel’s NASH candidate met its primary endpoint of liver fat reduction in Phase II, the data put it near the bottom of the pack in an already-crowded field.  In the Phase IIa STAMP-NAFLD trial,...
BioCentury | Sep 25, 2020
Translation in Brief

Jackson Labs shows mesenchymal cells trigger lung neutrophils to feed lipids to metastases; plus Vir and Poxel

Neutrophils fuel breast cancer lung metastasisIn a Nature article, a team led by The Jackson Laboratory scientists showed in mice that blocking macropinocytosis could reduce lung metastasis by breast tumor cells. They revealed that interactions with lung mesenchymal cells...
BioCentury | Sep 19, 2020
Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

Passage Bio’s frontotemporal dementia gene therapyUniversity of Pennsylvania spinout Passage Bio Inc. reported that administration of PBFT02, an AAV1-GRN vector, led to elevated levels of PGRN in the brain and cerebral spinal fluid (CSF), reduced lysosomal...
Items per page:
1 - 10 of 1551